3 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Opioid Withdrawal: new trials by email Literature Review of Opioid Withdrawal trials Research Report on Opioid Withdrawal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS) - Opioid Withdrawal, Chronic Pain | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 240 | 2024-08-12 | 2026-11-05 |
| Sublingual Dexmedetomidine for Treating Opioid Withdrawal BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Active not recruiting | New York State Psychiatric Institute | 160 | 2023-02-28 | 2026-10-28 |
| Oral Cannabidiol for Opioid Withdrawal Epidiolex, Placebo - Opioid Withdrawal, Opioid Craving | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 3 | 2020-11-01 | 2023-08-29 |
| Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Dexmedetomidine, Placebo - Opioid Withdrawal | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 225 | 2020-06-09 | 2026-08-11 |
| Oxytocin Treatment of Opioid Dependence Intranasal Oxytocin Spray, Placebo - Opioid Dependence, Opioid Withdrawal | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 12 | 2016-02-01 | 2019-08-07 |
Opioid-Related Disorders (5) · Chronic Pain (1) · Morphine Dependence (1) · Psychomotor Agitation (1) · Recurrence (1) · Substance-Related Disorders (1)
Chemically-Induced Disorders (5) · Mental Disorders (5) · Narcotic-Related Disorders (5) · Substance-Related Disorders (4) · Pathological Conditions, Signs and Symptoms (3) · Neurologic Manifestations (2) · Signs and Symptoms (2) · Aberrant Motor Behavior in Dementia (1) · Behavior (1) · Behavioral Symptoms (1) · Disease Attributes (1) · Dyskinesias (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Pain (1)
Cannabidiol (1) · Dexmedetomidine (1) · Transcranial Magnetic Stimulation (1) · lofexidine (1)
BioXcel Therapeutics Inc (1) · Clive Michelsen (1) · Johns Hopkins University (1) · Medical University of South Carolina (1) · New York State Psychiatric Institute (1) · University of North Carolina, Chapel Hill (1)
United States (6)
BioXcel MM, MD (1) · Cecilia L Bergeria, PhD (1) · Cort A Pedersen, MD (1) · James C Garbutt, MD (1) · Kelly Barth (1) · Sandra Comer, Ph.D (1)
R01DA058620 (1), UG3DA056247-01 (1)